molindone has been researched along with ziprasidone in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ernsberger, P; Hufeisen, SJ; Jayathilake, K; Kroeze, WK; Meltzer, HY; Popadak, BA; Renock, SM; Roth, BL; Steinberg, S | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Allison, DB; Cappelleri, JC; Chandler, LP; Heo, M; Infante, MC; Mentore, JL; Weiden, PJ | 1 |
1 review(s) available for molindone and ziprasidone
| Article | Year |
|---|---|
Antipsychotic-induced weight gain: a comprehensive research synthesis.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Confidence Intervals; Drug Administration Schedule; Humans; Molindone; Piperazines; Placebos; Psychotic Disorders; Research Design; Thiazoles; Treatment Outcome; Weight Gain | 1999 |
2 other study(ies) available for molindone and ziprasidone
| Article | Year |
|---|---|
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Humans; Protein Binding; Receptors, Histamine H1; Statistics, Nonparametric; Weight Gain | 2003 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |